

# CITATION REPORT

List of articles citing

## Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

DOI: 10.2337/dc17-0417

Diabetes Care, 2018, 41, 258-266.

**Source:** <https://exaly.com/paper-pdf/69684819/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
276	Semaglutide-the "" in the field of glucagon-like peptide-1 receptor agonists?. <b>2017</b> , 5, 475		7
275	Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis. <b>2018</b> , 97, e0420		3
274	A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1149-1167	3.6	25
273	Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. <b>2018</b> , 57, 1571-1580		56
272	Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?. <b>2018</b> , 14, 371-377		9
271	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <b>2018</b> , 6, 275-286		270
270	Semaglutide: First Global Approval. <b>2018</b> , 78, 275-284		32
269	GLP-1 receptor agonists and cardiovascular protection: A class effect or not?. <b>2018</b> , 44, 193-196		15
268	Glucagon-like peptide 1 in health and disease. <b>2018</b> , 14, 390-403		187
267	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2291-2297	6.7	20
266	Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. <b>2018</b> , 27, 1301-1309		2
265	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. <b>2018</b> , 35, 531-544		7
264	The mode and mechanism of action of once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes. <b>2018</b> , 30, S12-S18		0
263	Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?. <b>2018</b> , 30, S19-S28		0
262	Clinical and Investigative Endocrinology and Diabetes. <b>2018</b> , 24 Suppl 2, 1-22		0
261	Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?. <b>2018</b> , 20, 113		16
260	Semaglutide once-weekly: improved efficacy with a new safety warning. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 1061-1072	3.8	7

259	Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes. <b>2018</b> , 30, S29-S42		2
258	Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. <b>2018</b> , 24, S14-S29		4
257	Semaglutide for the Treatment of Type 2 Diabetes Mellitus. <i>Journal of Pharmacy Technology</i> , <b>2018</b> , 34, 281-289	0.6	1
256	Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus. <b>2018</b> , 24, S30-S41		7
255	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2255-2263	6.7	39
254	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2210-2219	6.7	44
253	Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2238-2245	6.7	12
252	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <b>2018</b> , 1864, 2814-2821		60
251	Typ-2-Diabetes [Update 2018]. <b>2018</b> , 14, 294-308		1
250	Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1087-1095	4	9
249	Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes. <b>2018</b> , 52, 1224-1232		3
248	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 576	5.6	18
247	Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients. <b>2018</b> , 6,		11
246	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , <b>2018</b> , 41, 1926-1937	14.6	34
245	The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. <b>2018</b> , 62, 535-545		9
244	Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2426-2434	6.7	8
243	The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. <b>2018</b> , 20, S233-S241		14
242	Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. <i>Diabetes Therapy</i> , <b>2018</b> , 9, 1533-1547	3.6	15

241	Clinical pharmacology of glucagon-like peptide-1 receptor agonists. <b>2018</b> , 17, 333-350		26
240	Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. <b>2018</b> , 57, 1529-1538		13
239	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. <b>2019</b> , 43, 136-145		26
238	Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 43-51	6.7	11
237	Advances in the treatment of diabetic retinopathy. <b>2019</b> , 33, 107417		27
236	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. <b>2019</b> , 13, 2985-2996		6
235	Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. <b>2019</b> ,		16
234	Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features. <b>2019</b> , 39, 805-819		32
233	Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1645-1717	3.6	17
232	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. <b>2019</b> , 98, 104-111		7
231	Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 2183-2199	3.6	16
230	Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. <b>2019</b> , 2, e00082		4
229	Subclavian vein stent: Two decades of unassisted patency. <b>2019</b> , 23, 504-505		
228	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <b>2019</b> , 45, 409-418		54
227	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1733-1752	3.6	26
226	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2272-2281	14.6	128
225	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <b>2019</b> , 7, 834-844		81
224	Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2315-2326	6.7	7

223	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <b>2019</b> , 18, 73		33
222	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. <b>2019</b> , 394, 39-50		186
221	Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. <b>2019</b> , 7, 528-539		105
220	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <b>2019</b> , 381, 841-851		567
219	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. <b>2019</b> , 36, 2034-2051		5
218	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1297-1317	3.6	14
217	Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Diabetologica</i> , <b>2019</b> , 56, 1051-1060	3.9	5
216	Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemc control in Sweden. <b>2019</b> , 22, 997-1005		12
215	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. <b>2019</b> , 321, 1466-1480		138
214	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. <b>2019</b> , 36, 1190-1199		5
213	Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives. <b>2019</b> , 14, 421-431		8
212	Diabetic Pharmacotherapies in Kidney Disease. <b>2019</b> , 49-74		
211	GREATER COMBINED REDUCTIONS IN HbA 1c AND WEIGHT LOSS WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES. <b>2019</b> , 25, 589-597		6
210	Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. <b>2019</b> , 13, 731-738		14
209	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. <b>2019</b> , 7, 356-367		102
208	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. <b>2019</b> , 3, 537-550		13
207	Bioactive peptides with antidiabetic properties: a review. <b>2019</b> , 54, 1909-1919		37
206	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 501-510	4	9

205	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 155	5.7	181
204	Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes. <b>2019</b> , 8, e1801509		13
203	Semaglutide as a promising antiobesity drug. <b>2019</b> , 20, 805-815		33
202	Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. <b>2019</b> , 9, e023458		6
201	The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. <b>2019</b> , 2019, 8083417		0
200	[Glucagon-like peptide-1 (GLP1) and the gastrointestinal tract. ]. <b>2019</b> , 160, 1927-1934		
199	Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. <b>2019</b> , 35, e3070		104
198	Obesity and type 2 diabetes: Also linked in therapeutic options. <b>2019</b> , 66, 140-149		1
197	Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 159-176	3.6	7
196	Obesity and type 2 diabetes: Also linked in therapeutic options. <b>2019</b> , 66, 140-149		6
195	Cracking the combination: Gut hormones for the treatment of obesity and diabetes. <b>2019</b> , 31, e12664		17
194	A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. <b>2019</b> , 105, 1213-1223		39
193	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 611-621	6.7	21
192	Antidiabetic Effect of Abextide, a Long-Acting Exendin-4 Analogue in Cynomolgus Monkeys. <b>2019</b> , 8, e1800686		3
191	Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. <b>2019</b> , 45, 102-109		10
190	Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). <b>2020</b> , 46, 100-109		96
189	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. <b>2020</b> , 23, 193-203		10
188	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. <b>2020</b> , 36, 209-211		1

187	Efficacy of semaglutide versus liraglutide in clinical practice. <b>2020</b> , 46, 515-517		10
186	Incretins in obesity and diabetes. <b>2020</b> , 1461, 104-126		32
185	Assessing patient PREFERENCE between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 355-364	6.7	20
184	Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 303-314	6.7	6
183	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 442-451	6.7	44
182	Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. <b>2020</b> , 105,		9
181	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. <b>2020</b> , 63, 473-485		11
180	Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. <b>2020</b> , 45 Suppl 1, 7-16		1
179	A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. <b>2020</b> , 45 Suppl 1, 17-27		16
178	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <b>2020</b> , 19, 156		10
177	Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. <b>2020</b> , 45 Suppl 1, 28-42		3
176	Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <b>2020</b> , 2020, 1626484		2
175	Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. <b>2020</b> , 38, 390-402		12
174	A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction. <b>2020</b> , 182, 114209		9
173	Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist. <b>2020</b> , 42, 2100-2116		1
172	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <b>2020</b> , 229, 61-69		53
171	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 analyses. <b>2020</b> , 10, e037883		3
170	Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. <b>2020</b> , 13, 4221-4234		6



169	Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. <b>2020</b> , 42, 1738-1749.e1			2
168	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 2125-2135	4		6
167	Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. <b>2020</b> , 45 Suppl 1, 43-60			11
166	Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. <b>2020</b> , 8, 880-893			27
165	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. <b>2020</b> , 132, 26-36			8
164	Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management. <b>2020</b> , 33, 3-18			4
163	GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. <b>2020</b> , 132, 3-14			15
162	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. <b>2020</b> , 105,			5
161	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	4.5		11
160	Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor. <b>2020</b> , 15, 1340-1348			5
159	Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study). <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2013-2020	6.7		16
158	Semaglutide injection for the treatment of adults with type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 675-684	3.8		3
157	Once-Weekly Semaglutide Reduces HbA and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 1061-1075	3.6		2
156	Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1328-1338	6.7		15
155	Practical guidance for use of oral semaglutide in primary care: a narrative review. <b>2020</b> , 132, 687-696			1
154	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data. <b>2020</b> , 13, 433-438			9
153	Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. <b>2020</b> , 106, 154190			14
152	Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. <b>2020</b> , 41, 3346-3358			60



151	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. <b>2020</b> , 37, 1248-1259		3
150	The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. <b>2020</b> , 11, 76-86		10
149	The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 509-521	3.6	4
148	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1339-1347	6.7	8
147	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 178	5.7	43
146	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. <b>2020</b> , 107, 154242		8
145	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. <b>2020</b> , 9, e015323		6
144	Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial. <b>2021</b> , 38, 550-561		3
143	Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance. <b>2021</b> , 75, e13731		11
142	Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 136-146	6.7	5
141	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 404-414	6.7	14
140	Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. <b>2021</b> , 45, 282-290		2
139	The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 754-762	6.7	29
138	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. <b>2021</b> , 17, 227-244		28
137	The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. <b>2021</b> , 21, 221-233		2
136	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. <b>2021</b> , 15, 59-68		3
135	Neutral effect of exenatide on serum testosterone in men with type 2 diabetes mellitus: A prospective cohort. <b>2021</b> , 9, 792-800		1
134	GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. <b>2021</b> , 17, 2050-2068		12

133	Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 879-896	3.6	5
132	Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 943-954	3.6	5
131	A Review on the Efficacy and Safety of Oral Semaglutide. <b>2021</b> , 21, 133-148		2
130	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. <b>2021</b> , 60, 1171-1185		3
129	An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. <b>2021</b> , 2, 100082		2
128	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. <b>2021</b> , 325, 1403-1413		113
127	Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 1475-1489	3.6	5
126	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 645507	5.7	5
125	Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 701446	5.6	1
124	Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. <b>2021</b> , 385, 503-515		119
123	Obesity and GLP-1. <b>2021</b> , 46, 168-176		4
122	Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 645617	5.7	5
121	Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. <b>2021</b> , 36, 109374		6
120	How glucagon-like peptide 1 receptor agonists work. <b>2021</b> , 10, R200-R212		4
119	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 645563	5.7	7
118	Development of Cagrilintide, a Long-Acting Amylin Analogue. <b>2021</b> , 64, 11183-11194		11
117	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. <b>2021</b> , 398, 262-276		35
116	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. <b>2021</b> , 31, 3257-3270		4

115	Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic. <b>2021</b> , 38, e14655		5
114	Semaglutide and the risk of diabetic retinopathy-current perspective. <b>2021</b> ,		0
113	Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2269-2278	6.7	7
112	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. <b>2021</b> , 178, 108931		6
111	Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. <b>2021</b> , 9,		1
110	Future perspectives in diabetes treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review). <b>2021</b> , 22, 1167		2
109	Oral semaglutide in the management of type 2 DM: Clinical status and comparative analysis. <b>2021</b> ,		
108	Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980-2020.		1
107	Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.. <b>2021</b> , 20, 2121-2128		1
106	Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?. <b>2021</b> , 22,		1
105	Recent developments in GLP-1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23 Suppl 3, 30-39	6.7	3
104	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. <b>2021</b> , 9, 563-574		11
103	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. <b>2021</b> , 171, 105782		9
102	Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. <i>Diabetes Therapy</i> , <b>2021</b> , 12, 2891-2905	3.6	4
101	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study. <b>2021</b> , 15, 871-878		5
100	Structure and dynamics of semaglutide and taspoglutide bound GLP-1R-Gs complexes.		1
99	Pharmacological treatment of hyperglycemia in type 2 diabetes. <b>2021</b> , 131,		24
98	GLP-1 receptor agonists: an updated review of head-to-head clinical studies. <b>2021</b> , 12, 2042018821997320		23

97	Treatment Options for Poor Responders to Bariatric Surgery. <b>2020</b> , 9, 364-372		4
96	Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints. <b>2020</b> , 46, 272-279		5
95	[New glucose-lowering drugs for reducing cardiovascular risk in patients with type2 diabetes mellitus]. <b>2019</b> , 36, 145-161		3
94	Safety of injectable semaglutide for type 2 diabetes. <b>2020</b> , 19, 785-798		5
93	Semaglutide lowers body weight in rodents via distributed neural pathways. <b>2020</b> , 5,		94
92	Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 695182	5.6	0
91	A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 24, 302	6.7	3
90	Les traitements mēdicamenteux de l'ob̄s̄it̄. <b>2017</b> , 47, 304-309		1
89	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. <b>2018</b> , 6, 129		
88	Neue Arzneimittel 2018. <b>2019</b> , 61-175		1
87	Clinical potential of treatment with semaglutide in type 2 diabetes patients. <b>2019</b> , 8, 212585		2
86	Wegovy (semaglutide): a new weight loss drug for chronic weight management. <b>2021</b> ,		8
85	Semaglutide for type 2 diabetes. <b>2020</b> , 43, 137-139		
84	[Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines]. <b>2020</b> , 60, 122-133		
83	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2022</b> , 1	10.5	4
82	GLP-1 Receptor Agonists as Adjunctive Treatment for Type 1 Diabetes: Renewed Opportunities through Tailored Approaches?. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	3
81	Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.. <b>2022</b> , 15, 155-163		1
80	Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report. <b>2022</b> , 13, 22-35		1

79	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice.. <i>Diabetes Therapy</i> , <b>2022</b> , 13, 225	3.6	2
78	GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice.. <b>2022</b> , 34, 418-440		0
77	Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.. <b>2022</b> , 1		3
76	Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.. <i>Frontiers in Pharmacology</i> , <b>2022</b> , 13, 831364	5.6	0
75	New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.. <i>Frontiers of Medicine</i> , <b>2022</b> , 16, 17	12	0
74	Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , <b>2022</b> , 16, 824054	5.1	1
73	Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.. <i>Clinical Pharmacology: Advances and Applications</i> , <b>2022</b> , 14, 19-26	1.5	
72	A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada.. <i>Cardiovascular Endocrinology and Metabolism</i> , <b>2022</b> , 11, e0260	2.5	
71	Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.. <i>Diabetes Therapy</i> , <b>2022</b> , 13, 551	3.6	2
70	GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	0
69	The efficacy and safety of once-weekly semaglutide in Japanese subjects with type 2 diabetes by baseline age and body mass index.. <i>Journal of Diabetes Investigation</i> , <b>2022</b> ,	3.9	2
68	The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?. <i>Journal of Obesity and Metabolic Syndrome</i> , <b>2022</b> ,	4.4	1
67	Injectable semaglutide and reductions in HbA1c and weight in the real-world in people switched from alternative glucagon-like peptide 1 receptor agonists.. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	0
66	Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.. <i>BMJ Open Diabetes Research and Care</i> , <b>2022</b> , 10,	4.5	1
65	Semaglutide for the Treatment of Obesity.. <i>Trends in Cardiovascular Medicine</i> , <b>2021</b> ,	6.9	3
64	Possibilities of a new glucagon-like peptide-1 receptor agonist Semaglutide in improving left ventricular diastolic function in a patient with arterial hypertension and type 2 diabetes mellitu. <i>Systemic Hypertension</i> , <b>2021</b> , 18, 186-192	1.6	
63	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.. <i>Biomedicines</i> , <b>2021</b> , 10,	4.8	2
62	Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. <b>2022</b> , 527-553		

61	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	2
60	Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression - real-world clinical practice. <i>CKJ: Clinical Kidney Journal</i> ,	4.5	0
59	Image_1.tif. <b>2018</b> ,		
58	Image_2.tif. <b>2018</b> ,		
57	Image_3.tif. <b>2018</b> ,		
56	Table_1.DOCX. <b>2018</b> ,		
55	Table_2.DOCX. <b>2018</b> ,		
54	Table_3.DOCX. <b>2018</b> ,		
53	Table_4.DOCX. <b>2018</b> ,		
52	Table_5.DOCX. <b>2018</b> ,		
51	Table_6.DOCX. <b>2018</b> ,		
50	Pharmacological profile of once-weekly injectable semaglutide for chronic weight management.. <i>Expert Review of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	1
49	Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial.. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	2
48	Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , <b>2022</b> ,	2.2	1
47	Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison.. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	3
46	Once-Weekly Semaglutide for Weight Management: A Clinical Review. <i>Journal of Pharmacy Technology</i> , 875512252210926	0.6	0
45	Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2022</b> , 16, 102511	8.9	0
44	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. <i>Frontiers in Pharmacology</i> , 13,	5.6	1

43	The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. <i>Contemporary Clinical Trials Communications</i> , <b>2022</b> , 100944	1.8	0
42	GLP-1 Receptor Agonists. <b>2022</b> , 130-160		
41	The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 1-13	4	1
40	A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> ,	10.5	0
39	Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 13,	5.7	0
38	Real-life effects of adding weekly subcutaneous semaglutide to insulin for the treatment of type 2 diabetes mellitus. <i>Revista Clínica Española</i> , <b>2022</b> ,	0.5	
37	Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. <i>Acta Diabetologica</i> ,	3.9	0
36	Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. <i>World Journal of Clinical Cases</i> , <b>2022</b> , 10, 6759-6768	1.6	0
35	Efficacy and safety of oral semaglutide in Russian patients with type 2 diabetes: subgroup analysis of PIONEER 1, 2, 3 trials. <b>2022</b> , 25, 204-214		
34	Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.		1
33	Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective.		1
32	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. <b>2022</b> ,		8
31	Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.		0
30	Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. <b>2022</b> , 11, 4938		0
29	Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. <b>2022</b> ,		0
28	Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2. <b>2022</b> , 22, 1-9		0
27	Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain. 13,		0
26	Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. <b>2022</b> , 21,		0



25	Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. 13,	0
24	Pharmacotherapy of type 2 diabetes: An update and future directions. <b>2022</b> , 137, 155332	3
23	Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. <b>2022</b> , 12, 1915	0
22	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence. <b>2022</b> , 27, 107424842211463	1
21	Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.	0
20	An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised BasalBolus Insulin in Type 2 Diabetes.	0
19	Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). <b>2022</b> ,	0
18	Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence.	0
17	Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.	0
16	GLP-1R Signaling and Functional Molecules in Incretin Therapy. <b>2023</b> , 28, 751	0
15	Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. <b>2023</b> , 13, 87	0
14	Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01). 13,	0
13	Efficacy of semaglutide: an evidence-based review.	0
12	Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Volume 16, 4449-4461	0
11	Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.	0
10	Medicines for Obesity: Appraisal of Clinical Studies with Grading of Recommendations, Assessment, Development, and Evaluation Tool. <b>2023</b> , 15, 606	0
9	Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. 1-7	0
8	Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. <b>2023</b> , 16, 161-176	0

- 7 Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. **2023**, 38, 25-33 ○
- 6 Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study. ○
- 5 Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review. **2023**, ○
- 4 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. **2023**, 365-396 ○
- 3 Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. **2023**, 28, 3094 ○
- 2 Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin: a case series. **2023**, 13, 204512532311651 ○
- 1 Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. **2023**, 14, 1005-1021 ○